CLINICAL & PIPELINE·Drug Approval
Novartis Secures Full FDA Approval for Fabhalta in IgA Nephropathy, Bolstering Renal Portfolio
Novartis has achieved full FDA approval for Fabhalta in IgA nephropathy, marking a critical milestone for patients at risk of kidney function decline. This transition from accelerated approval solidifies Fabhalta's market position, demanding robust supply chain scaling and strategic commercial planning from Novartis Pharmaceutical Corp to meet anticipated demand and ensure broad patient access.
90-Day Activity